Noopept (N-phenylacetyl-L-polyglycine ethyl ester) is a relatively new and promising nootropic compound that is known for its potent effects (Ostrovskaia, Gudasheva, Voronina & Seredenin, 2002). Noopept was formed based on its derivative action and similar pharmalogical properties to Piracetam, where Noopept requires one thousandth of the dose of Piracetam (Ostovskaia et al., 2002). Though Piracetam is able to accentuate early memory functions, Noopept works to facilitate the further memory processes of consolidation and retrieval, including spatial memory (Ostovskaia et al., 2002; Ostrovskaya et al., 2007). Noopepts actions can be pinned down to its antioxidant and anti-inflammatory effects as well as capacity to inhibit neurotoxicity caused by neuronal excitation caused by overabundant calcium and/or glutamate, and also produces improvements in microcirculation (Ostovskaia et al., 2002; Kovalenko et al., 2002a).
Benefits and Effects
- Improves cognition associated through neuroprotective effects through antioxidant, mitochondrial and intracellular stabilization, including aptosis and excitotoxicity reduction (Ostrovskaya et al., 2014);
- Promotes neurogenesis through promotion of neuron growth maintenance, and increases in NGF and BDNF (Ostrovskaya et al., 2014; Ostrovskaya et al., 2008);
- Shown to promote cognitive regeneration in animal models with Alzheimer disease (Ostrovskaya et al., 2014);
- Holds neuroprotective and moderating effect in laboratory studies of Parkinson’s disease (Jia et al., 2011);
- Neuroprotective effects seen both in vivo (brain ischemia) and in vitro (neuronal representations) (Ostrovskaia et al., 2002);
- Increases blood serum antibodies creating an immunotropic effect (Ostrovskaya et al., 2007);
- Shown to lack toxicity in high-doses during animal studies (Kovalenko et al., 2002b).
5mg to 10mg
Jia, X., Gharibyan, A. L., Öhman, A., Liu, Y., Olofsson, A., & Morozova-Roche, L. A. (2011). Neuroprotective and nootropic drug Noopept rescues α-synuclein amyloid cytotoxicity. Journal of molecular biology, 414(5), 699-712. DOI: 10.1016/j.jmb.2011.09.044
Kovalenko, L. P., Miramedova, M. G., Alekseeva, S. V., Gudasheva, T. A., Ostrovskaia, R. U., & Seredenin, S. B. (2002a). Anti-inflammatory properties of Noopept (dipeptide nootropic agent GVS-111). Eksperimental’naia i klinicheskaia farmakologiia, 65(2), 53-55.
Kovalenko, L. P., Smol’nikova, N. M., Alekseeva, S. V., Nemova, E. P., Sorokina, A. V., Miramedova, M. G., … & Kulakova, A. V. (2002b). Preclinical study of noopept toxicity. Eksperimental’naia i klinicheskaia farmakologiia, 65(1), 62-64.
Ostrovskaia, R. U., Gudasheva, T. A., Voronina, T. A., & Seredenin, S. B. (2002). The original novel nootropic and neuroprotective agent noopept. Eksperimental’naia i klinicheskaia farmakologiia, 65(5), 66-72. Retrieved from http://europepmc.org/abstract/med/12596521
Ostrovskaya, R. U., Gruden, M. A., Bobkova, N. A., Sewell, R. D., Gudasheva, T. A., Samokhin, A. N., … & Morozova-Roche, L. A. (2007). The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model. Journal of psychopharmacology, 21(6), 611-619. DOI: 10.1177/0269881106071335
Ostrovskaya, R. U., Gudasheva, T. A., Zaplina, A. P., Vahitova, J. V., Salimgareeva, M. H., Jamidanov, R. S., & Seredenin, S. B. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of experimental biology and medicine, 146(3), 334-337. DOI: /10.1007/s10517-008-0297-x
Ostrovskaya, R. U., Vakhitova, Y. V., Kuzmina, U. S., Salimgareeva, M. K., Zainullina, L. F., Gudasheva, T. A., … & Seredenin, S. B. (2014). Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Journal of biomedical science, 21(1), 74. DOI: 10.1186/s12929-014-0074-2